Valsartan: Again remembering blood pressure due to contamination



Impurities in active ingredients
Valsartan: remember blood pressure

Blood pressure in the review: Again, there is a recall of valsartan, an ingredient in antihypertensive drugs. What should you consider now and why consulting with a doctor is very important.

Photo: iStock / digicomphoto

Blood pressure in the review: Again, there is a recall of valsartan, an ingredient in antihypertensive drugs. What should you consider now and why consulting with a doctor is very important.

The Valsartan blood pressure agent is once again in criticism – again, producer drugs are remembered because impurities have been found. Which collection is considered and what must be considered by patients now.

Previous withdrawals since July 2018 are not enough. Now more drugs from drug manufacturers are recalled. This is about one more valsartan recallBut this time the drug came from another manufacturer. Batch of Mylan Laboratories Limited is affected at this time – this drug manufacturer may not be produced until further notice for the production of drugs with valsartan.

Valsartan remembers: This collection is affected

Valsartan is a hypotensive agent used in various high blood pressure medications. It is produced by various manufacturers throughout the world. Dirt has now been found in certain traceable batches from Mylan Laboratories Limited of India.

This is N-nitrosodiethylamine (NDEA), a substance that can cause cancer. Fabrics can be formed in the production of valsartan, if not working quite clean.

In a statement, the company mentions affected products and batches:

  • Valsartan dura: 40 mg, 80 mg, 160 mg and 320 mg; 28, 56 and 98 film-coated tablets; PZN 09239582, 09239599, 09239607, 09239613, 09239636, 09333803 and 09333826
  • Valsartan / HCT (Valsartan, Hydrochlorothiazide) Mylan: 80 mg / 12.5 mg, 160 mg / 12.5 mg, 160 mg / 25 mg, 320 mg / 12.5 mg, 320 mg / 25 mg; 6 and 98 film-coated tablets; PZNs 10054959, 10054965, 10054971, 10054988, 10054994, 10055002, 10055019, 10055025, 10055025, 10055031 and 10055048

What Patients Must Do Now: Don't Just End Therapy!

important: Anyone who finds these drugs and batches each with the indicated PZN (central pharmacy number) cannot stop therapy in a hurry!

Talk to your doctor. Cancer risk, according to company announcements, is not worth the risk that arises when blood pressure drugs are stopped suddenly. Because the effects of hypertension are not treated faster.

Already increased Sartanen withdrawal

Withdrawal of hypotensive drugs is not the first. It was not until the beginning of July that the Valsartan groups were withdrawn due to impurity, and the number of messages slowly increased. At the time it was a valsartanhaltige drug from Chinese manufacturer Zhejiang Huahai Pharmaceuticals, here carcinogenic substances were found. In September, there were reports that even anti-hypertension from the Indian plant Hetero Labs was contaminated and hence remembered.

In addition, a batch of Irbesartan Heumann 300 mg drugs is currently being recalled, as reported by the German Hypertension League.

Even though there is a recall and possible risk of cancer: Don't just stop taking medication!

Sartan is one of the agents used to treat high blood pressure and heart failure and to help with various cardiovascular diseases. Even after a heart attack, preparation is often used.

Sartane is not alone in criticism. Recently, a study found that blood pressure drugs with ACE inhibitors can cause lung cancer. Cardiologists are skeptical.

However, as with contaminated sartan, blood pressure-lowering drugs should not be stopped this way, consultation with a doctor or pharmacist is absolutely necessary. Because of the risk, which originates from illegal cessation, according to the German Hypertension League, many times higher than the potential risk of cancer coming out. Doctors recommend that you belong to a risk group and identify with you if you need a substitute medication.

Following is a list of all Sartan drugs withdrawn including PZN. So far, drugs from Novartis and TAD Pharma and Aurobindo must not be affected. However, the German Pharmacist newspaper stressed that pharmacies already affected by the package should no longer be found. Consult your pharmacist, you must be sure!


Source link